Neutrophil-Derived IL-1β Impairs the Efficacy of NF-κB Inhibitors against Lung Cancer

Cell Reports

Volumn 16, Issue 1, 2016, Pages 120-132

  McLoed, Allyson G ^a   Sherrill, Taylor P ^b   Cheng, Dong Sheng ^b   Han, Wei ^b   Saxon, Jamie A ^a   Gleaves, Linda A ^b   Wu, Pingsheng ^b   Polosukhin, Vasiliy V ^b   Karin, Michael ^c   Yull, Fiona E ^a,d   Stathopoulos, Georgios T ^b,e,f   Georgoulias, Vassilis ^g   Zaynagetdinov, Rinat ^b   Blackwell, Timothy S ^a,b,d,h  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

^e UNIVERSITY OF PATRAS   (Greece)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^h DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CATHEPSIN G; CISPLATIN; DOXYCYCLINE; GEMCITABINE; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; K RAS PROTEIN; URETHAN; I KAPPA B KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; EPITHELIUM CELL; HUMAN; IN VIVO STUDY; LUNG CARCINOGENESIS; MOUSE; NEUTROPHIL COUNT; NON SMALL CELL LUNG CANCER; NONHUMAN; PHASE 2 CLINICAL TRIAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN PROCESSING; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOGENESIS; DRUG EFFECTS; LUNG TUMOR; METABOLISM; NEUTROPHIL; PATHOLOGY; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS;

ANIMALS; BORTEZOMIB; CARCINOGENESIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; EPITHELIAL CELLS; HUMANS; I-KAPPA B KINASE; INTERLEUKIN-1BETA; LUNG NEOPLASMS; MICE; MYELOID CELLS; NEUTROPHILS; NF-KAPPA B; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS;

EID: 85008157542     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.05.085     Document Type: Article

References (47)

1. Bassères, D.S., Ebbs, A., Levantini, E., Baldwin, A.S., Requirement of the NF-kappaB subunit p65/RelA for K-Ras-induced lung tumorigenesis. Cancer Res. 70 (2010), 3537–3546.
2. Bassères, D.S., Ebbs, A., Cogswell, P.C., Baldwin, A.S., IKK is a therapeutic target in KRAS-Induced lung cancer with disrupted p53 activity. Genes Cancer 5 (2014), 41–55.
3. Besse, B., Planchard, D., Veillard, A.S., Taillade, L., Khayat, D., Ducourtieux, M., Pignon, J.P., Lumbroso, J., Lafontaine, C., Mathiot, C., Soria, J.C., Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer. Lung Cancer 76 (2012), 78–83.
4. Chen, W., Li, Z., Bai, L., Lin, Y., NF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy target. Front. Biosci. (Landmark Ed.) 16 (2011), 1172–1185.
5. Chen, L.C., Wang, L.J., Tsang, N.M., Ojcius, D.M., Chen, C.C., Ouyang, C.N., Hsueh, C., Liang, Y., Chang, K.P., Chen, C.C., Chang, Y.S., Tumour inflammasome-derived IL-1β recruits neutrophils and improves local recurrence-free survival in EBV-induced nasopharyngeal carcinoma. EMBO Mol. Med. 4 (2012), 1276–1293.
6. Cogswell, J.P., Godlevski, M.M., Wisely, G.B., Clay, W.C., Leesnitzer, L.M., Ways, J.P., Gray, J.G., NF-kappa B regulates IL-1 beta transcription through a consensus NF-kappa B binding site and a nonconsensus CRE-like site. J. Immunol. 153 (1994), 712–723.
7. Enzler, T., Sano, Y., Choo, M.K., Cottam, H.B., Karin, M., Tsao, H., Park, J.M., Cell-selective inhibition of NF-κB signaling improves therapeutic index in a melanoma chemotherapy model. Cancer Discov. 1 (2011), 496–507.
8. Everhart, M.B., Han, W., Sherrill, T.P., Arutiunov, M., Polosukhin, V.V., Burke, J.R., Sadikot, R.T., Christman, J.W., Yull, F.E., Blackwell, T.S., Duration and intensity of NF-kappaB activity determine the severity of endotoxin-induced acute lung injury. J. Immunol. 176 (2006), 4995–5005.
9. Fanucchi, M.P., Fossella, F.V., Belt, R., Natale, R., Fidias, P., Carbone, D.P., Govindan, R., Raez, L.E., Robert, F., Ribeiro, M., et al. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 24 (2006), 5025–5033.
10. Fisher, G.H., Wellen, S.L., Klimstra, D., Lenczowski, J.M., Tichelaar, J.W., Lizak, M.J., Whitsett, J.A., Koretsky, A., Varmus, H.E., Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 15 (2001), 3249–3262.
11. Fleming, T.J., Fleming, M.L., Malek, T.R., Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6-8C5 mAb to granulocyte-differentiation antigen (Gr-1) detects members of the Ly-6 family. J. Immunol. 151 (1993), 2399–2408.
12. Fong, C.H.Y., Bebien, M., Didierlaurent, A., Nebauer, R., Hussell, T., Broide, D., Karin, M., Lawrence, T., An antiinflammatory role for IKKbeta through the inhibition of “classical” macrophage activation. J. Exp. Med. 205 (2008), 1269–1276.
13. Fridlender, Z.G., Albelda, S.M., Tumor-associated neutrophils: friend or foe?. Carcinogenesis 33 (2012), 949–955.
14. Fridlender, Z.G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., Worthen, G.S., Albelda, S.M., Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell 16 (2009), 183–194.
15. Gabrilovich, D.I., Nagaraj, S., Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9 (2009), 162–174.
16. Giannou, A.D., Marazioti, A., Spella, M., Kanellakis, N.I., Apostolopoulou, H., Psallidas, I., Prijovich, Z.M., Vreka, M., Zazara, D.E., Lilis, I., et al. Mast cells mediate malignant pleural effusion formation. J. Clin. Invest. 125 (2015), 2317–2334.
17. Gibbs, J.B., Mechanism-based target identification and drug discovery in cancer research. Science 287 (2000), 1969–1973.
18. Greten, F.R., Eckmann, L., Greten, T.F., Park, J.M., Li, Z.W., Egan, L.J., Kagnoff, M.F., Karin, M., IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118 (2004), 285–296.
19. Greten, F.R., Arkan, M.C., Bollrath, J., Hsu, L.C., Goode, J., Miething, C., Göktuna, S.I., Neuenhahn, M., Fierer, J., Paxian, S., et al. NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell 130 (2007), 918–931.
20. Guma, M., Ronacher, L., Liu-Bryan, R., Takai, S., Karin, M., Corr, M., Caspase 1-independent activation of interleukin-1beta in neutrophil-predominant inflammation. Arthritis Rheum. 60 (2009), 3642–3650.
21. Hagemann, T., Lawrence, T., McNeish, I., Charles, K.A., Kulbe, H., Thompson, R.G., Robinson, S.C., Balkwill, F.R., “Re-educating” tumor-associated macrophages by targeting NF-kappaB. J. Exp. Med. 205 (2008), 1261–1268.
22. Hsu, L.C., Enzler, T., Seita, J., Timmer, A.M., Lee, C.Y., Lai, T.Y., Yu, G.Y., Lai, L.C., Temkin, V., Sinzig, U., et al. IL-1β-driven neutrophilia preserves antibacterial defense in the absence of the kinase IKKβ. Nat. Immunol. 12 (2011), 144–150.
23. Huang, H.J., Sugimoto, S., Lai, J., Okazaki, M., Yamamoto, S., Krupnick, A.S., Kreisel, D., Gelman, A.E., Maintenance of IKKβ activity is necessary to protect lung grafts from acute injury. Transplantation 91 (2011), 624–631.
24. Karabela, S.P., Psallidas, I., Sherrill, T.P., Kairi, C.A., Zaynagetdinov, R., Cheng, D.S., Vassiliou, S., McMahon, F., Gleaves, L.A., Han, W., et al. Opposing effects of bortezomib-induced nuclear factor-κB inhibition on chemical lung carcinogenesis. Carcinogenesis 33 (2012), 859–867.
25. Langereis, J.D., Raaijmakers, H.A.J.A., Ulfman, L.H., Koenderman, L., Abrogation of NF-κB signaling in human neutrophils induces neutrophil survival through sustained p38-MAPK activation. J. Leukoc. Biol. 88 (2010), 655–664.
26. Li, C., Wang, C., Current evidences on IL1B polymorphisms and lung cancer susceptibility: a meta-analysis. Tumour Biol. 34 (2013), 3477–3482.
27. Li, Z.W., Omori, S.A., Labuda, T., Karin, M., Rickert, R.C., IKK beta is required for peripheral B cell survival and proliferation. J. Immunol. 170 (2003), 4630–4637.
28. Lin, Y., Bai, L., Chen, W., Xu, S., The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin. Ther. Targets 14 (2010), 45–55.
29. Lind, H., Haugen, A., Zienolddiny, S., Differential binding of proteins to the IL1B -31 T/C polymorphism in lung epithelial cells. Cytokine 38 (2007), 43–48.
30. Maksimowicz, T., Chyczewska, E., Chyczewski, L., Nikliński, J., Ostrowska, H., Szyszko, J., Furman, M., Activity and tissue localization of cathepsin G in non small cell lung cancer. Rocz. Akad. Med. Bialymst. 42:Suppl 1 (1997), 199–216.
31. Meylan, E., Dooley, A.L., Feldser, D.M., Shen, L., Turk, E., Ouyang, C., Jacks, T., Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 462 (2009), 104–107.
32. Rajnavolgyi, E., Nagy, L., Galdiero, M.R., Bonavita, E., Barajon, I., Garlanda, C., Mantovani, A., Jaillon, S., Tumor associated macrophages and neutrophils in cancer. Immunobiology 218 (2013), 1402–1410.
33. Saxon, J.A., Sherrill, T.P., Polosukhin, V.V., Sai, J., Zaynagetdinov, R., McLoed, A.G., Gulleman, P.M., Barham, W., Cheng, D.S., Hunt, R.P., et al. Epithelial NF-κB signaling promotes EGFR-driven lung carcinogenesis via macrophage recruitment. OncoImmunology, 2016, 10.1080/2162402X.2016.1168549 Published online March 30, 2016.
34. Sionov, R.V., Fridlender, Z.G., Granot, Z., The multifaceted roles neutrophils play in the tumor microenvironment. Cancer Microenviron. 8 (2015), 125–158.
35. Stathopoulos, G.T., Sherrill, T.P., Cheng, D.S., Scoggins, R.M., Han, W., Polosukhin, V.V., Connelly, L., Yull, F.E., Fingleton, B., Blackwell, T.S., Epithelial NF-kappaB activation promotes urethane-induced lung carcinogenesis. Proc. Natl. Acad. Sci. USA 104 (2007), 18514–18519.
36. Stathopoulos, G.T., Sherrill, T.P., Karabela, S.P., Goleniewska, K., Kalomenidis, I., Roussos, C., Fingleton, B., Yull, F.E., Peebles, R.S. Jr., Blackwell, T.S., Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion. Am. J. Respir. Crit. Care Med. 182 (2010), 1273–1281.
37. Takahashi, H., Ogata, H., Nishigaki, R., Broide, D.H., Karin, M., Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell 17 (2010), 89–97.
38. Tichelaar, J.W., Zhang, Y., leRiche, J.C., Biddinger, P.W., Lam, S., Anderson, M.W., Increased staining for phospho-Akt, p65/RELA and cIAP-2 in pre-neoplastic human bronchial biopsies. BMC Cancer, 5, 2005, 155.
39. Tuveson, D.A., Shaw, A.T., Willis, N.A., Silver, D.P., Jackson, E.L., Chang, S., Mercer, K.L., Grochow, R., Hock, H., Crowley, D., et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5 (2004), 375–387.
40. Wang, L., Zhang, L.F., Wu, J., Xu, S.J., Xu, Y.Y., Li, D., Lou, J.T., Liu, M.F., IL-1β-mediated repression of microRNA-101 is crucial for inflammation-promoted lung tumorigenesis. Cancer Res. 74 (2014), 4720–4730.
41. Westcott, P.M.K., Halliwill, K.D., To, M.D., Rashid, M., Rust, A.G., Keane, T.M., Delrosario, R., Jen, K.Y., Gurley, K.E., Kemp, C.J., et al. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature 517 (2015), 489–492.
42. Xia, Y., Yeddula, N., Leblanc, M., Ke, E., Zhang, Y., Oldfield, E., Shaw, R.J., Verma, I.M., Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model. Nat. Cell Biol. 14 (2012), 257–265.
43. Xue, W., Meylan, E., Oliver, T.G., Feldser, D.M., Winslow, M.M., Bronson, R., Jacks, T., Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma. Cancer Discov. 1 (2011), 236–247.
44. Yang, J., Hawkins, O.E., Barham, W., Gilchuk, P., Boothby, M., Ayers, G.D., Joyce, S., Karin, M., Yull, F.E., Richmond, A., Myeloid IKKβ promotes antitumor immunity by modulating CCL11 and the innate immune response. Cancer Res. 74 (2014), 7274–7284.
45. You, M., Candrian, U., Maronpot, R.R., Stoner, G.D., Anderson, M.W., Activation of the Ki-ras protooncogene in spontaneously occurring and chemically induced lung tumors of the strain A mouse. Proc. Natl. Acad. Sci. USA 86 (1989), 3070–3074.
46. Zaynagetdinov, R., Sherrill, T.P., Polosukhin, V.V., Han, W., Ausborn, J.A., McLoed, A.G., McMahon, F.B., Gleaves, L.A., Degryse, A.L., Stathopoulos, G.T., et al. A critical role for macrophages in promotion of urethane-induced lung carcinogenesis. J. Immunol. 187 (2011), 5703–5711.
47. Zaynagetdinov, R., Stathopoulos, G.T., Sherrill, T.P., Cheng, D.S., McLoed, A.G., Ausborn, J.A., Polosukhin, V.V., Connelly, L., Zhou, W., Fingleton, B., et al. Epithelial nuclear factor-κB signaling promotes lung carcinogenesis via recruitment of regulatory T lymphocytes. Oncogene 31 (2012), 3164–3176.